NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants Jae-Sik ShinSeung-Woo HongTae Won Kim PRECLINICAL STUDIES 31 October 2013 Pages: 389 - 399
CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model Chang Hoon MoonSeung Ju LeeYoung Joo Min PRECLINICAL STUDIES 08 November 2013 Pages: 400 - 411
SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres Doris Mangiaracina BenbrookBaskar NammalwarK. Darrell Berlin PRECLINICAL STUDIES Open access 20 November 2013 Pages: 412 - 423
Radiosensitizing activity of a novel Benzoxazine through the promotion of apoptosis and inhibition of DNA repair Suraj RadhamaniChristopher BradleyJasim Al-Rawi PRECLINICAL STUDIES 14 March 2014 Pages: 424 - 435
A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors D. S. HongR. KurzrockP. LoRusso PHASE I STUDIES 22 November 2013 Pages: 436 - 444
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors Sharad GhamandeChia-Chi LinSanjay Goel PHASE I STUDIES 24 November 2013 Pages: 445 - 451
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors E. M. DunbarB. S. CoatsP. W. Stacpoole PHASE I STUDIES 03 December 2013 Pages: 452 - 464
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies Siqing FuMing-Mo HouRazelle Kurzrock PHASE I STUDIES 05 December 2013 Pages: 465 - 472
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer Yoshito KomatsuTakayuki YoshinoAtsushi Ohtsu PHASE I STUDIES Open access 15 December 2013 Pages: 473 - 480
Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours Lot A. DevrieseKevin M. KochJan H. M. Schellens PHASE I STUDIES 19 December 2013 Pages: 481 - 488
Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia Kevin R. KellyThomas C. SheaSwaminathan Padmanabhan Iyer PHASE I STUDIES Open access 20 December 2013 Pages: 489 - 499
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies Francois GoldwasserSandrine FaivreEric Raymond PHASE I STUDIES 07 January 2014 Pages: 500 - 509
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer Carolyn D. BrittenAlex A. AdjeiPatricia M. LoRusso PHASE I STUDIES 07 January 2014 Pages: 510 - 517
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors Margaret von MehrenCarolyn D. BrittenStephen Leong PHASE I STUDIES Open access 24 January 2014 Pages: 518 - 525
Phase II trial of vorinostat in advanced melanoma N. B. HaasI. QuirtA. Oza PHASE II STUDIES 25 January 2014 Pages: 526 - 534
Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab Jeeyun LeeYong Sang HongWon Ki Kang PHASE II STUDIES 28 January 2014 Pages: 535 - 541
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach Allyson J. OceanPaul ChristosMaureen E. Lane PHASE II STUDIES 15 February 2014 Pages: 542 - 548
A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer Alan L. HoBrynna L. LipsonDavid G. Pfister PHASE II STUDIES 25 February 2014 Pages: 549 - 554
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial A. NecchiP. GiannatempoF. De Braud PHASE II STUDIES 26 February 2014 Pages: 555 - 560
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer Jeeyun LeeSang Joon ShinHyun Cheol Chung PHASE II STUDIES 27 February 2014 Pages: 561 - 568
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer Audrey BellesoeurEdith CartonFrançois Goldwasser SHORT REPORT 08 January 2014 Pages: 569 - 572
Successful readministration of trastuzumab after severe immune reactions in two breast cancer patients R. TanzN. MeillanC. Chargari SHORT REPORT 29 March 2014 Pages: 573 - 574
Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer Carolyn D. BrittenAlex A. AdjeiPatricia M. LoRusso Erratum 09 February 2014 Pages: 575 - 575
